The LOVE Act adds a new subsection to section 1881 of the Social Security Act to create an 8-year Medicare demonstration that pays transplant-performing hospitals the reasonable costs of running living kidney donor transplant facilitator training programs. The Secretary of HHS must set up the demonstration within 180 days of enactment, may waive provisions of title XVIII as needed to implement it, and must collect and report multi-year outcome and cost data to Congress.
This bill matters because it uses Medicare dollars to underwrite a workforce intervention aimed at increasing living kidney donation — a clinical pathway that can improve patient outcomes and reduce long-term dialysis costs. For transplant centers, payers, and health system leaders, the proposal creates new funding for facilitation but raises questions about program design, measurement, and whether payments will cover real startup and operating expenses.
At a Glance
What It Does
The Secretary must establish an 8-year demonstration and annually pay each eligible hospital an amount equal to the hospital’s reasonable costs for operating a living kidney donor transplant facilitator training program. The statute defines eligibility as hospitals where kidney transplants are performed and explicitly authorizes waivers of Medicare provisions to run the demo.
Who It Affects
Transplant hospitals that perform kidney transplants, hospital administrators who manage transplant programs, transplant coordinators and new facilitator personnel, Medicare administrators at CMS, and dialysis providers whose volumes could decline if more patients receive transplants.
Why It Matters
The bill ties Medicare reimbursement to a non-clinical, workforce-building intervention rather than to a procedure or device. If successful, it could shift a portion of ESRD care from dialysis to transplant and establish a model for funding upstream interventions that affect downstream costs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The LOVE Act creates a time-limited Medicare demonstration to pay hospitals for training individuals who help Medicare beneficiaries with end-stage renal disease (ESRD) find and move through the living kidney donation process. The program reimburses participating hospitals for the ‘‘reasonable costs’’ of operating such training each year of the eight-year demonstration; the Secretary must stand up the demonstration within 180 days of the law taking effect.
Participation is limited to hospitals that already perform kidney transplants.
The bill specifies what facilitator training must aim to do: train people to assist ESRD beneficiaries in identifying prospective living donors and to help beneficiaries navigate the donation process. The law calls these trained individuals “facilitators.” It does not prescribe a national curriculum, certification pathway, or specific staffing model, leaving those operational details to hospitals and the Secretary during implementation.To evaluate impact, the statute requires an initial report to Congress not later than six years after enactment that compares a five-year span following enactment to the five years before enactment on measures such as increases in living donors and living-donor transplants, recipient outcomes, and Medicare cost savings from reduced dialysis.
The Secretary must then submit updates for two additional years. The bill also authorizes qualitative interviews of facilitators, volunteers, donors and recipients to supplement quantitative metrics.Finally, the Secretary has express authority to waive provisions of title XVIII as necessary to run the demonstration.
That clause is broad and intended to give CMS flexibility on implementation matters such as payment mechanisms, eligibility details, or reporting requirements, but it also shifts many practical decisions to the administrative rulemaking and demo-design process.
The Five Things You Need to Know
The Secretary of HHS must establish the demonstration within 180 days of enactment and run it for eight years.
Payments to participating hospitals are annual amounts equal to the Secretary’s determination of the hospital’s reasonable costs for operating a living kidney donor transplant facilitator training program.
Only hospitals in which kidney transplants are performed are eligible to participate in the demonstration.
The training programs must prepare individuals to (A) help Medicare beneficiaries with ESRD identify prospective living kidney donors and (B) help those beneficiaries navigate the donation process.
CMS must deliver an initial report to specified congressional committees not later than six years after enactment comparing the five years after enactment to the five years before on donor and transplant counts, recipient outcomes, estimated Medicare cost savings, and qualitative findings, followed by two annual updates.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishment and duration of the demonstration
This paragraph directs the Secretary to create an eight-year demonstration program and to begin payments to eligible hospitals each year of the demonstration. The 180-day clock forces a relatively quick startup, which will require CMS to issue guidance, define payment flows, and recruit participating hospitals on a compressed timeline. The eight-year duration is long enough to allow multi-year outcome measurement but also limits the program to a fixed demonstration rather than a permanent entitlement.
Eligibility: transplant-performing hospitals
Eligibility is straightforward: hospitals that perform kidney transplants may participate. That narrows the field to transplant centers but does not differentiate by volume, academic status, or prior experience with donor outreach. Practically, this means low-volume centers could enter if they perform transplants, while high-volume centers likely stand to receive the largest absolute payments and produce the majority of measured outcomes.
Definition and scope of trainer/facilitator programs
The statute defines the training program by its functional goals (identifying prospective living donors and helping beneficiaries navigate the donation process) rather than by curriculum or credentialing. That leaves decisions about who serves as a facilitator (clinical coordinators, social workers, trained volunteers, or new nonclinical roles) and what competencies are required to hospitals and CMS. The operational ambiguity allows flexibility but creates a need for CMS to specify standards if the program aims for consistent quality and comparable outcomes across sites.
Waiver authority for Medicare provisions
The Secretary may waive provisions of title XVIII as necessary to implement the demo. In practice, CMS could use that authority to modify payment rules, eligibility verifications, or data submission requirements for participating hospitals. That flexibility can expedite implementation but also concentrates discretion in the agency and raises governance questions about what waivers are used and how beneficiary protections are preserved.
Evaluation and reporting requirements
CMS must report quantitative and qualitative program outcomes to the House Ways and Means and Energy and Commerce Committees and the Senate Finance Committee. The initial report is due six years after enactment and must compare the five years after enactment to the five years before on donor counts, transplant counts, recipient outcomes, and estimated Medicare cost savings. The law’s explicit comparison window sets the evaluation baseline but will require CMS to reconcile differences in registry data, case-mix, and secular trends when attributing changes to the demonstration.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries with ESRD — Facilitators aim to increase access to living-donor transplantation, which generally yields better survival and quality-of-life outcomes than long-term dialysis.
- Living kidney donors and prospective donors — Training and navigation support can reduce informational and logistical barriers to donation and improve pre-donation counseling and follow-up.
- Transplant hospitals and transplant programs — The demonstration reimburses costs associated with building facilitator training capacity, reducing the cash burden for program start-up and operation.
- Medicare program/policymakers — If the demo reduces dialysis reliance, the program could produce measurable Medicare savings down the line and provide evidence for scaling similar interventions.
- Clinical and nonclinical workforce (coordinators, social workers, navigators) — New funded roles and training pathways may create employment and professional development opportunities within transplant programs.
Who Bears the Cost
- Medicare Trust Fund/CMS — The demonstration increases Medicare spending in the short term for annual facility payments and administrative oversight, with cost-savings contingent on downstream effects.
- Participating hospitals — Hospitals must implement, staff, and report on training programs; if CMS’s ‘‘reasonable costs’’ determination underpays, hospitals may subsidize operations or limit program scale.
- CMS/Department of HHS — Agency staff must design the demo, issue regulations or guidance, monitor compliance, conduct evaluation and produce multi-year reports, creating administrative workload and potential need for resources.
- Dialysis providers — An increase in transplants could reduce dialysis volumes and revenue in some settings, creating financial pressure for providers dependent on steady patient loads.
- Small or resource-limited transplant centers — They may face start-up challenges even with cost reimbursement if upfront investments or administrative capacity are required before payments flow.
Key Issues
The Core Tension
The central tension is between using Medicare funds to incentivize a workforce intervention that could expand transplants and save downstream dialysis costs, and the risk that short-term payments and loose implementation rules will produce uneven uptake, weak evidence, or perverse incentives (such as prioritizing volume over donor suitability). Policymakers must balance building enough flexibility to pilot models against setting standards that preserve patient safety and produce credible evaluation.
Several implementation questions and trade-offs could shape whether the demonstration delivers the intended results. First, the statute ties reimbursement to ‘‘reasonable costs’’ but does not define the calculation method, allowable cost categories, or whether payments will be prospective or cost-settled through existing Medicare cost-reporting mechanisms.
Those decisions determine whether hospitals receive adequate and timely funding to build programs and will affect participation incentives.
Second, attribution and measurement are difficult. The mandated evaluation compares five-year windows before and after enactment, but secular trends, regional variations in donation culture, changes in transplant practice, and concurrent policy initiatives could confound estimates of program effect.
The qualitative interview component helps contextualize results but cannot substitute for robust causal identification. Finally, the broad waiver authority gives CMS flexibility but raises concerns about preserving beneficiary safeguards and maintaining consistent standards for facilitator training across sites; without minimum credentialing or monitoring requirements, program quality could vary significantly and skew outcome assessments.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.